Softwr

Healthcare · head to head

Lunit vs NextGen Enterprise EHR

Lunit logo

Lunit

Healthcare

FDA cleared and CE marked AI for mammography, tomosynthesis and chest radiography

From
On request
Rated
-
Full reviewWebsite
NextGen Enterprise EHR logo

NextGen Enterprise EHR

Healthcare

Enterprise-grade EHR and RCM for large healthcare organizations

From
On request
Rated
-
Full reviewWebsite

The short version

  • Each has a real cost: Lunit the regulatory permission differs by product and by region, and INSIGHT Risk has been filed with the FDA but not cleared, so a buyer who reads a corporate press release rather than the specific clearance for their product and jurisdiction will plan a deployment they cannot legally run.; NextGen Enterprise EHR no pricing published on website
  • They diverge on capability: Lunit covers Lunit INSIGHT MMG, NextGen Enterprise EHR covers Electronic Health Records.
  • Prices and features above were last checked on 1 September 2026.

Where they differ

Only the attributes on which Lunit and NextGen Enterprise EHR actually diverge.

Attributes where Lunit and NextGen Enterprise EHR differ
AttributeLunitNextGen Enterprise EHR
PlatformsWebWeb, Desktop
FoundedUnknown1997

Identical on both: starting price (On request), pricing model (quote), free tier (No), user rating (Not yet rated), category (Healthcare).

What each one covers

Drawn from each product's published feature list. An absence here means we hold no record of it - not that the product lacks it.

Only in Lunit

  • Lunit INSIGHT MMG
  • Lunit INSIGHT DBT
  • Lunit INSIGHT CXR
  • Volpara density assessment
  • Volpara RiskPathways
  • Volpara dose tracking
  • PACS and mammography workstation integration

Only in NextGen Enterprise EHR

  • Electronic Health Records
  • Clinical Documentation
  • Revenue Cycle Management
  • Patient Management
  • Analytics
  • Interoperability
  • Reporting
  • HL7

What people use each for

The jobs each tool is most often brought in to do.

Lunit

  • A national breast screening programme evaluating AI as a second reader to reduce double reading workload where two human readers are currently mandatednot NextGen Enterprise EHR
  • A breast centre that moved to tomosynthesis and now has reading times it cannot staff, wanting detection support on DBT specificallynot NextGen Enterprise EHR
  • An American breast imaging centre needing automated volumetric density assessment to meet patient density notification requirements, which is what Volpara is bought fornot NextGen Enterprise EHR
  • A tuberculosis or lung screening programme in a high volume, radiologist scarce setting using chest radiography triage to prioritise filmsnot NextGen Enterprise EHR

NextGen Enterprise EHR

  • Patient Carenot Lunit
  • Medical Recordsnot Lunit
  • Practice Managementnot Lunit
  • Telehealthnot Lunit

Where each one falls short

Documented limitations, not opinions. Every one is a constraint you would hit in normal use.

Lunit

  • The regulatory permission differs by product and by region, and INSIGHT Risk has been filed with the FDA but not cleared, so a buyer who reads a corporate press release rather than the specific clearance for their product and jurisdiction will plan a deployment they cannot legally run.
  • Detection AI changes recall rates in screening, and the downstream cost of additional diagnostic workup lands on the programme rather than on the software budget, which is the cost most screening business cases omit.
  • Performance is sensitive to the mammography vendor and acquisition protocol, so published results from a Hologic estate do not transfer to a GE or Siemens estate without local validation the buyer must fund.
  • MMG, DBT and CXR are licensed separately and Volpara modules are separate again, so a breast centre wanting detection, density and risk pathways is assembling four line items rather than buying one product.
  • Using AI as a replacement for one of two human readers is a workforce and liability decision that regulators and professional bodies treat differently in each country, so the saving that justifies the purchase may not be permitted where you operate.

NextGen Enterprise EHR

  • No pricing published on website

Pricing, plan by plan

Lunit

On request
  • Lunit INSIGHT$undefined/year
    • Priced per study or per annual examination volume by product
    • MMG, DBT and CXR licensed separately
    • Volpara density and RiskPathways modules quoted separately

NextGen Enterprise EHR

On request

No published plan breakdown. See the NextGen Enterprise EHR review.

Which should you pick?

Choose Lunit if

  • You need lunit insight mmg.
  • You also want lunit insight dbt.
Lunit review

Choose NextGen Enterprise EHR if

  • You need electronic health records.
  • You work on Web, Desktop.
  • You also want clinical documentation.
NextGen Enterprise EHR review

Questions people ask

Is Lunit or NextGen Enterprise EHR better?
Neither clearly leads. Lunit starts at On request and NextGen Enterprise EHR at On request, and user ratings are close enough to be indistinguishable. Choose on capability and platform support.
Which is cheaper, Lunit or NextGen Enterprise EHR?
Lunit starts at On request and NextGen Enterprise EHR at On request.
Does Lunit or NextGen Enterprise EHR run on more platforms?
Lunit runs on Web. NextGen Enterprise EHR runs on Web, Desktop.
What is Lunit best used for?
Lunit is most often used for a national breast screening programme evaluating ai as a second reader to reduce double reading workload where two human readers are currently mandated, a breast centre that moved to tomosynthesis and now has reading times it cannot staff, wanting detection support on dbt specifically, an american breast imaging centre needing automated volumetric density assessment to meet patient density notification requirements, which is what volpara is bought for, a tuberculosis or lung screening programme in a high volume, radiologist scarce setting using chest radiography triage to prioritise films. Of those, a national breast screening programme evaluating ai as a second reader to reduce double reading workload where two human readers are currently mandated and a breast centre that moved to tomosynthesis and now has reading times it cannot staff, wanting detection support on dbt specifically are not what NextGen Enterprise EHR is typically brought in for.
What can Lunit do that NextGen Enterprise EHR cannot?
Lunit covers Lunit INSIGHT MMG, Lunit INSIGHT DBT, Lunit INSIGHT CXR, Volpara density assessment. NextGen Enterprise EHR covers Electronic Health Records, Clinical Documentation, Revenue Cycle Management, Patient Management.

Answered from the vendors’ own pages

Lunit: Is Lunit FDA cleared?

Yes for specific products. INSIGHT MMG, INSIGHT DBT and INSIGHT CXR Triage hold FDA 510(k) clearances. INSIGHT Risk, the five year risk prediction model, has been filed but was not cleared at the time of writing.

NextGen Enterprise EHR: What is NextGen Enterprise EHR pricing?

NextGen Healthcare does not publish pricing for its Enterprise solutions on their website. The company uses a consultative sales model where pricing is determined after understanding specific practice requirements and needed features.

Source
Lunit: Can Lunit replace a second human reader in screening?

That depends entirely on your jurisdiction and professional body guidance, not on the software. The CE mark permits clinical use; it does not authorise a workforce model.

Lunit: What did the Volpara acquisition add?

Volumetric breast density measurement, dose tracking and RiskPathways high risk programme management, which are the things American breast centres buy for density notification compliance rather than for detection.

Lunit: Is pricing published?

No. It is quoted per study or per annual volume, by product, with on premises and cloud priced differently.

Share

Related pages

More on Lunit

More on NextGen Enterprise EHR

Keep looking

Other head to heads